FDA names drugmakers potentially acting to delay cheap generics

(Reuters) – The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp , Johnson & Johnson , Gilead Sciences and Novartis AG , who the regulator says are potentially blocking access to samples of their drugs to delay generic competition.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *